PBP Stock Overview
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Probiotec Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.84 |
| 52 Week High | AU$2.94 |
| 52 Week Low | AU$2.14 |
| Beta | 0.44 |
| 1 Month Change | 2.16% |
| 3 Month Change | 0.35% |
| 1 Year Change | 20.34% |
| 3 Year Change | 42.00% |
| 5 Year Change | 83.23% |
| Change since IPO | 145.89% |
Recent News & Updates
Shareholder Returns
| PBP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -0.4% | -4.8% | -3.0% |
| 1Y | 20.3% | 30.9% | 3.9% |
Return vs Industry: PBP underperformed the Australian Pharmaceuticals industry which returned 30.9% over the past year.
Return vs Market: PBP exceeded the Australian Market which returned 3.9% over the past year.
Price Volatility
| PBP volatility | |
|---|---|
| PBP Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PBP has not had significant price volatility in the past 3 months.
Volatility Over Time: PBP's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Wes Stringer | www.probiotec.com.au |
Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials.
Probiotec Limited Fundamentals Summary
| PBP fundamental statistics | |
|---|---|
| Market cap | AU$230.96m |
| Earnings (TTM) | AU$8.69m |
| Revenue (TTM) | AU$221.22m |
26.6x
P/E Ratio1.0x
P/S RatioIs PBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBP income statement (TTM) | |
|---|---|
| Revenue | AU$221.22m |
| Cost of Revenue | AU$154.96m |
| Gross Profit | AU$66.25m |
| Other Expenses | AU$57.57m |
| Earnings | AU$8.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 29.95% |
| Net Profit Margin | 3.93% |
| Debt/Equity Ratio | 52.5% |
How did PBP perform over the long term?
See historical performance and comparison